News Conference News ACC 2025 RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up Michael O'Riordan April 08, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Conference News ACC 2023 Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions Michael O'Riordan March 07, 2023
News Conference News ACC 2023 PULSED AF ‘Strengthens the Case’ for Pulsed-Field Ablation in AF Todd Neale March 06, 2023
News Opinion Editor's Corner ACC 2023 What’s Going to Be Hot at ACC/WCC 2023? Shelley Wood February 27, 2023
News Conference News ACC 2022 Managing AF Patients Undergoing PCI—Some Lingering Questions Michael O'Riordan April 12, 2022
News Conference News ACC 2022 BIO|GUARD-MI: Post-MI Arrhythmia Monitoring Falls Short Todd Neale April 11, 2022
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Conference News ACC 2021 Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III Todd Neale May 15, 2021
News Conference News ACC 2020 Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS Todd Neale April 03, 2020
Presentation ACC 2019 Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Presenter: Renato Lopes March 18, 2019
News Conference News ACC 2019 AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI Caitlin E. Cox March 17, 2019
News Conference News ACC 2019 ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend Shelley Wood March 11, 2019
Presentation ACC 2018 Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants Presenter: Steve Deitelzweig March 12, 2018
News Conference News ACC 2017 My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time Shelley Wood March 23, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017